exclusive license agreement

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

More than 10.000 documents for exclusive license agreement

- BioLineRx Signs Exclusive License Agreement with Yissum for Oral Phase II Ready Treatment BL-7040 for Inflammatory Bowel Disease.
JERUSALEM -- BioLineRx (TASE:BLRX), a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfe...
- Business Wire
- June 27, 2011
- 4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat.
PLANEGG-MARTINSRIED, Germany & TOKYO -- 4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of...
- Business Wire
- April 14, 2011
- The Swatch Group Ltd. Signs Exclusive License Agreement with Liquidmetal Technologies.
BIEL/BIENNE, Switzerland & RANCHO SANTA MARGARITA, Calif. -- Liquidmetal([R]) Technologies Inc. (OTCBB: LQMT) and The Swatch Group Ltd. (SWX: UHR/UHR ...
- Business Wire
- March 10, 2011

- Shionogi Enters into Exclusive License Agreement with QuatRx Pharmaceuticals to Market Ospemifene.
OSAKA, Japan -- Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter "Shionogi") and QuatRx Pharmaceuticals Company (Head Of...
- Business Wire
- March 02, 2010
- 4SC Announces Exclusive License Agreement for Japan with Yakult Honsha for the Oral HDAC Inhibitor Resminostat.
PLANEGG-MARTINSRIED, Germany -- 4SC AG (Frankfurt, Prime Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced the grant of an excl...
- Business Wire
- April 14, 2011
- ETView Medical, Ltd., Announces Exclusive Patent License Agreement - 2/2/2012.
Agreement Establishes an Exclusive US License for 2 Patents in the Airway Management Market TEL AVIV, Israel -- ETView Medical Ltd. (TASE: ETVW) ann...
- Business Wire
- February 20, 2012
- TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program.
TESARO will be responsible for worldwide development and commercialization Amgen's oral, small molecule ALK inhibitors are highly potent and selecti...
- Business Wire
- March 22, 2011
- Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
To Develop and Market OpRegen(TM) for the Treatment of Age-Related Macular Degeneration JERUSALEM & ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTIM...
- Business Wire
- October 11, 2010
- Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305.
CAMBRIDGE, Mass. & LAUSANNE, Switzerland -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicine...
- Business Wire
- August 06, 2009
- Unigene to Advance Phase 2 Development of Oral PTH Program by Entering into an Amended and Restated Exclusive Worldwide License Agreement with GSK.
Phase 2 study for treatment of osteoporosis in postmenopausal women expected to commence in Q1 2011; Unigene to receive $4M upfront for development co...
- Business Wire
- December 13, 2010